<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03475797</url>
  </required_header>
  <id_info>
    <org_study_id>RC17_0013</org_study_id>
    <nct_id>NCT03475797</nct_id>
  </id_info>
  <brief_title>Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias</brief_title>
  <acronym>StimO</acronym>
  <official_title>Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias: a Multicentric, Controlled, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medically intractable pain caused by occipital neuralgia can be very difficult to control&#xD;
      with traditional pain management. Peripheral nerve stimulation which is used in migraines and&#xD;
      cluster headache can be an alternative for these patients with occipital neuralgias when&#xD;
      medical treatment and traditional pain management have failed (drugs for neuropathic pain,&#xD;
      infiltrations, psychobehavioral approaches and multidisciplinary approach in a pain center).&#xD;
      Occipital nerve stimulation consists to put a lead subcutaneously in front of the occipital&#xD;
      nerve and to connect the lead to a pulse generator. A retrospective study of 60 patients was&#xD;
      conducted in Nantes University Hospital. The results were good with the Visual Analog Scale&#xD;
      (VAS) decreased from 8.4 preoperatively to 2.85 postoperatively. The medical quantification&#xD;
      scale (MQS) was reduced to about 50% (18 preoperatively versus 9.9 postoperatively).&#xD;
      Stimulation was quiet stable over time with a mean follow-up of 24 months (range 6 to 72&#xD;
      months). The aim of StimO is to confirm this result through a national controlled randomized&#xD;
      multicenter study where occipital nerve stimulation will be compared to the optimal medical&#xD;
      management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's decision to stop the study prematurely due to insufficient inclusion.&#xD;
  </why_stopped>
  <start_date type="Actual">April 20, 2018</start_date>
  <completion_date type="Actual">September 3, 2021</completion_date>
  <primary_completion_date type="Actual">June 26, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of occipital nerve stimulation</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the decrease of pain (evaluated by visual analogic scale) after 6 months of treatment between the 2 groups (ONS / OMM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 3 months of occipital nerve stimulation in the ONS group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 6 months of occipital nerve stimulation in the ONS group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum pain (using Visual Analogic Scale)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Comparison of maximum pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average pain (using Visual Analogic Scale)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Comparison of average pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative decrease of pain (using Visual Analogic Scale) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of the relative decrease of pain (using Visual Analogic Scale) at 3 months between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative decrease of pain (using Visual Analogic Scale) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the relative decrease of pain (using Visual Analogic Scale) at 6 months between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (using EQ-5D-5L questionnaire)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Comparison of the quality of life (using EQ-5D-5L questionnaire) between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (using Hamilton Anxiety and Depression (HAD) scale)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Comparison of the quality of life (using Hamilton Anxiety and Depression (HAD) scale) between the 2 groups (ONS/OMM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Occipital Neuralgia</condition>
  <arm_group>
    <arm_group_label>Occipital Nerve Stimulation (ONS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Management (OMM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Medical Management according to what is done in routine clinical practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occipital nerve stimulation</intervention_name>
    <description>Occipital nerve stimulation with percutaneous or surgical lead</description>
    <arm_group_label>Occipital Nerve Stimulation (ONS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimal Medical Management</intervention_name>
    <description>Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.</description>
    <arm_group_label>Occipital Nerve Stimulation (ONS)</arm_group_label>
    <arm_group_label>Optimal Medical Management (OMM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18 and 85 years old&#xD;
&#xD;
          -  Chronic occipital neuralgias as defined by International Headache Society (IHS) more&#xD;
             than 6 months with permanent pain associated or not with paroxysm&#xD;
&#xD;
          -  Secondary occipital neuralgias (post-traumatic, post-surgery, major arthrosis,&#xD;
             compression or lesion of the occipital nerve …)&#xD;
&#xD;
          -  Chronic neuropathic pain according to the Neuropathic Pain Diagnostic Questionnaire&#xD;
             (DN4 ≥ 4)&#xD;
&#xD;
          -  Maximum pain on VAS ≥ 50/100&#xD;
&#xD;
          -  Failure of medical treatment (association of neuropathic medication like antiepileptic&#xD;
             and/or antidepressant and/or antalgic treatment like paracetamol, tramadol or&#xD;
             morphine) and pain management in a pain Unit including multidisciplinary approach,&#xD;
             physiotherapy, block test in C1-C2, radiofrequency rhizolysis, and/or corticosteroid&#xD;
             infiltration of C2 according to the criteria defined by Health Authorities for spinal&#xD;
             cord stimulation.&#xD;
&#xD;
          -  Reduction of pain with Transcutaneous Electrical Nerve Stimulation (TENS) in occipital&#xD;
             area&#xD;
&#xD;
          -  Neurological examen has to be completed and must be normal except for the occipital&#xD;
             neuralgia territory&#xD;
&#xD;
          -  A negative pregnancy test for women with childbearing potential&#xD;
&#xD;
          -  Women of childbearing potential must use appropriate method(s) of contraception during&#xD;
             the clinical trial&#xD;
&#xD;
          -  Patients must be capable of giving informed consent and must have signed informed&#xD;
             consent&#xD;
&#xD;
          -  Affiliation to an appropriate health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to the experimental medical devices&#xD;
&#xD;
          -  Titanium related allergies&#xD;
&#xD;
          -  Patients with contraindications to general anesthesia&#xD;
&#xD;
          -  Complete anaesthesia in the C2/Great occipital nerve territory&#xD;
&#xD;
          -  Drug or alcohol addiction&#xD;
&#xD;
          -  Psychiatric disorders (psychiatric evaluation)&#xD;
&#xD;
          -  Any medical or psychological problems which may interfere with a smooth conduction of&#xD;
             the study protocol (e.g. cancer with a limited life expectancy)&#xD;
&#xD;
          -  Need for intensive nursing care&#xD;
&#xD;
          -  Difficulty in follow-up&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Women not using contraception&#xD;
&#xD;
          -  Adults under a legal protection regime (guardianship, trusteeship, &quot;sauvegarde de&#xD;
             justice&quot;)&#xD;
&#xD;
          -  Exclusion period for another study&#xD;
&#xD;
          -  Simultaneous participation in another clinical trial except if that other trial does&#xD;
             not affect the StimO study as approved and documented by the sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Wertheimer</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Paris</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

